Tag: ankylosing spondylitis global market

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Ankylosing Spondylitis Market from 2024 to 2025?

The market for ankylosing spondylitis has experienced robust growth in the past few years. Its size is projected to surge from $5.9 billion in 2024 to $6.36 billion in 2025, marking a compound annual growth rate (CAGR) of 7.8%. The historical growth of this market owes to factors such as the discovery of hla-b27, advancements in biologic treatments, the advent of pain management techniques, heightened patient advocacy and awareness, as well as the use of NSAIDS and disease-modifying drugs.

What Is the Projected Market Size of the Ankylosing Spondylitis Market?

In the upcoming years, the market size of ankylosing spondylitis is projected to enjoy robust expansion. It’s forecasted to escalate to $8.71 billion by 2029 with a compound annual growth rate (CAGR) of 8.2%. The significant growth predicted for this period can be linked to factors such as the emergence of personalized medicine, the creation of novel biologics, early intervention and screenings, management of lifestyle and diet, and the implementation of telemedicine and remote monitoring. Notable trends within this forecast period encompass the availability of biosimilars, the focus on targeted pain therapies, the emphasis on patient reported outcomes (PROs), the existence of community support programs, and exploration into regenerative medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Who are the Major Competitors in the Ankylosing Spondylitis Market Outlook?

Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

What Is Fueling Growth in the Ankylosing Spondylitis Market?

The projected growth of the ankylosing spondylitis market is anticipated to be fuelled by the rise in the elderly population. The term “geriatric population” denotes an uptick in the number of older individuals resulting from shifts in population age structure. This demographic transition has escalated both the count and the ratio of individuals aged 60 and above. Therapies and medications for ankylosing spondylitis provide pain management and enhance mobility in geriatric patients suffering from the condition. For instance, future projections from the United Nations Department of Economic and Social Affairs (UN DESA), an agency of the UN Secretariat headquartered in the US, in January 2023, estimated that the global population of people aged 65 and above is set to double. The numbers are expected to swell from 761 million in 2021 to about 1.6 billion by 2050. Consequently, the burgeoning geriatric population is serving as a catalyst for the expansion of the ankylosing spondylitis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11962&type=smp

Which Ankylosing Spondylitis Market Segments Are Growing the Fastest?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

Which Industry Trends Are Shaping the Future of the Ankylosing Spondylitis Market?

The evolution of therapeutic strategies is an emerging trend gaining traction in the ankylosing spondylitis market. Key players in the ankylosing spondylitis sector are developing novel treatments to maintain their market presence. For instance, in April 2022, AbbVie Inc., a biopharmaceutical firm based in the United States, announced the U.S. Food and Drug Administration’s (FDA) approval of RINVOQ for treating adults suffering from active ankylosing spondylitis (AS). This furnishes a fresh oral treatment method for patients unresponsive to TNF blockers, indicating remarkable enhancement in disease indications such as backache and physical functioning. The fast effectiveness and safety credentials from clinical trials make it a significant advancement in managing this ongoing inflammatory ailment, broadening the therapeutic options available to patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Countries Are Leading the Ankylosing Spondylitis Market?

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11962

This Report Delivers Insight On:

1. How big is the ankylosing spondylitis market, and how is it changing globally?

2. Who are the major companies in the ankylosing spondylitis market, and how are they performing?

3. What are the key opportunities and risks in the ankylosing spondylitis market right now?

4. Which products or customer segments are growing the most in the ankylosing spondylitis market?

5. What factors are helping or slowing down the growth of the ankylosing spondylitis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the ankylosing spondylitis industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Ankylosing Spondylitis Market Size Shifted, And What Is the Outlook Through 2034?

In recent times, there has been a substantial surge in the size of the ankylosing spondylitis market. The growth is predicted to increase from $5.9 billion in the year 2024 to $6.36 billion by the end of 2025, reflecting a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the historic period include the discovery of hla-b27, advancement in biologic treatments, approaches to pain management, increased patient advocacy and awareness, and the use of NSAIDS and disease-modifying drugs.

Expectations are high for robust expansion in the ankylosing spondylitis market size in the ensuing years. The market is anticipated to balloon to $8.71 billion by 2029, with a compounded annual growth rate (CAGR) of 8.2%. The upswing during the forecast period can be ascribed to factors including the utilization of personalized medicine, the emergence of novel biologics, early interventions and screenings, management of lifestyle and diet, and the use of telemedicine and remote monitoring. Notable trends to watch for during the forecast period encompass the availability of biosimilars, specialized pain therapies, heightened emphasis on patient-reported outcomes (PROs), community-based support programs, and exploration of regenerative medicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Ankylosing Spondylitis Market?

The projected surge in the aging population is anticipated to drive the expansion of the ankylosing spondylitis market. The reference to the geriatric population signifies a rise in the percentage of older individuals resulting from alterations in a population’s age makeup. This demographic transformation has amplified the count and ratio of individuals above 60 years of age. Treatments and medications for ankylosing spondylitis aid in enhancing mobility and handling pain in older people with this condition. For example, in January 2023, estimates from the United Nations Department of Economic and Social Affairs (UN DESA), a department of the US-based UN Secretariat, predicted that the worldwide population of people aged 65 and above is poised to more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. Hence, the escalation in the geriatric population is fuelling the growth of the ankylosing spondylitis market.

Which Key Market Segments Comprise the Ankylosing Spondylitis Market and Drive Its Revenue Growth?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=11962&type=smp

Which Areas Are Leading Regions in the Ankylosing Spondylitis Market Expansion Across the Globe?

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theAnkylosing Spondylitis Market Direction?

The evolution of therapeutic solutions represents a prominent trend emerging in the ankylosing spondylitis market. Companies within this sector are pioneering new therapies to maintain their market standing. For instance, in April 2022, the U.S.-based biopharmaceutical firm, AbbVie Inc., declared the approval of RINVOQ by the U.S. Food and Drug Administration (FDA) for treating adults diagnosed with active ankylosing spondylitis (AS). This paves the way for a new orally administered treatment possibility for patients unresponsive to TNF blockers, demonstrating significant amelioration in symptoms like backache and physical functioning. The product’s prompt effectiveness and safety profile, determined through clinical trials, render it a pivotal advancement in the management of this chronic inflammatory ailment, thereby enhancing the array of therapeutic options accessible to patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

How Is the Ankylosing Spondylitis Market Conceptually Defined?

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints (the joints connecting the lower spine to the pelvis). It involves inflammation of the joints and entheses and affects joints, leading to pain, stiffness, and progressive loss of mobility in the spine.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11962

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Primary Drivers Are Supporting the Continued Market Growth of theAnkylosing Spondylitis Market?

The surge in the elderly population is predicted to fuel the expansion of the ankylosing spondylitis market. The term geriatric population pertains to a rise in the number of older people resulting from changes in a population’s age structure. This demographic transition has led to an increase in the number and percentage of people aged 60 and above. Treatments and medications for ankylosing spondylitis assist in enhancing mobility and managing pain among seniors suffering from this condition. For example, data from the United Nations Department of Economic and Social Affairs (UN DESA), a department of the UN Secretariat based in the US, predicts a significant increase in the global population of individuals aged 65 and above. The number is expected to more than double, rising from 761 million in 2021 to 1.6 billion by 2050. Therefore, the growth in the elderly population is facilitating the expansion of the ankylosing spondylitis market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

#What Long-Term Growth Rate is Expected for theAnkylosing Spondylitis Market Between 2025 and 2034?

There has been substantial growth in the ankylosing spondylitis market in the past few years. The market, which is poised to surge from $5.9 billion in 2024 to $6.36 billion in 2025, will experience a compound annual growth rate (CAGR) of 7.8%. This notable growth in the historic period can be credited to factors such as the discovery of hla-b27, the development of biologic treatments, methods for pain management, patient advocacy and awareness initiatives, NSAIDS, and disease-modifying drugs.

The market for ankylosing spondylitis is projected to witness robust growth in the coming years, with an estimated valuation of $8.71 billion by 2029. This signifies a compound annual growth rate (CAGR) of 8.2%. The projected growth during this period can be related to factors such as the individualized medicine approach, the creation of novel biologics, early screening and intervention, management of lifestyle and diet, and innovations in telemedicine and remote monitoring. Other significant trends for the forecast period encompass the availability of biosimilics, targeted pain treatments, a focus on patient-reported outcomes (pros), community support initiatives, and exploration of regenerative medicine.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11962

How Are Consumer Market Innovations Shaping the Current and Future Landscape of theAnkylosing Spondylitis Market?

Emerging therapeutic solutions are increasingly becoming a dominant trend in the ankylosing spondylitis market. Firms involved in the sector are progressing new treatments to maintain their market status. For example, in April 2022, leading American biopharma company AbbVie Inc. reported the endorsement of RINVOQ by the U.S. Food and Drug Administration (FDA) for the treatment of adults dealing with active ankylosing spondylitis (AS). This offers a novel oral solution for patients who have shown no response to TNF blockers, exhibiting remarkable enhancement in disease symptoms such as back pain and physical function. The swift efficiency and safety demonstrated in clinical trials position it as a significant breakthrough in managing this persistent inflammatory disease, extending the range of treatment options for patients.

Who Are the Key Market Players Influencing the Growth of the Corn and Ankylosing Spondylitis Industry?

Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Key Market Segments Comprise the Ankylosing Spondylitis Market and Drive Its Revenue Growth?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=11962&type=smp

Which Regions Are Emerging as Leaders in the Ankylosing Spondylitis Market?

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Gobal Ankylosing Spondylitis Maret 2025, By The Business Research Company:

Luxury Hair Care Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/luxury-hair-care-products-global-market-report

Retail And Wholesale Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/retail-and-wholesale-global-market-report

Personal Care Ingredients Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/personal-care-ingredients-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the ankylosing spondylitis market right now?

Over the past few years, the market size for ankylosing spondylitis has seen robust growth. It is predicted to rise from $5.9 billion in 2024 to $6.36 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. Several factors have spurred growth in the historical period, including the discovery of HLA-B27, the development of biologic treatments, advancements in pain management strategies, increased patient advocacy and awareness, the use of NSAIDS, and disease-modifying drugs.

How fast Is the ankylosing spondylitis market expected to grow, and what’s its future value?

In the coming years, the market size of ankylosing spondylitis is predicted to experience significant growth, anticipated to reach $8.71 billion by 2029 with a compound annual growth rate (CAGR) of 8.2%. This growth during the predicted timeframe can be credited to factors like the approach of personalized medicine, the evolution of novel biologics, early involvement and screenings, management of lifestyle and diet, as well as telemedicine and remote patient monitoring. The future market trends are expected to focus on the availability of biosimilars, targeted therapies for pain management, importance of patient-reported outcomes (pros), community-oriented support programs, and exploring regenerative medicine.

Get your ankylosing spondylitis market report here!

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

What are the leading drivers of growth in the ankylosing spondylitis market?

The rise in the elderly population is predicted to fuel the expansion of the ankylosing spondylitis market in future. The term “geriatric population” denotes an upsurge in the count of senior citizens driven by alterations in a population’s age composition. This demographic transition has escalated the quantity and percentage of individuals over 60 years old. Medications and treatments for ankylosing spondylitis assist in enhancing mobility and controlling pain among seniors afflicted with the condition. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a division of the UN Secretariat located in the US, projected that the worldwide count of those aged 65 and over would more than double, rising from 761 million in 2021 to 1.6 billion by 2050. Consequently, the swelling geriatric population is pushing the ankylosing spondylitis market’s growth.

What are the key segments defining the ankylosing spondylitis market?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Who are the key players steering the development of the ankylosing spondylitis market?

Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

What emerging trends are influencing the growth of the ankylosing spondylitis market?

The focus on the development of new therapeutic options is becoming a prevalent trend in the ankylosing spondylitis market. Ankylosing spondylitis enterprises are introducing innovative therapeutic options to maintain their market dominance. A prime example took place in April 2022 when US biopharmaceutical firm AbbVie Inc. received U.S. Food and Drug Administration (FDA) approval for RINVOQ, a medication designed for the treatment of adults suffering from active ankylosing spondylitis (AS). This opens up a new oral treatment pathway for patients who haven’t had success with TNF blockers, demonstrated by substantial improvements in disease symptoms like back pain and physical functioning. The swift effectiveness and safety profile exhibited in clinical trials position it as an important step forward in managing this chronic inflammatory disease, broadening the range of therapeutic options accessible to patients.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11962

Which regions are most influential in expanding the ankylosing spondylitis market?

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Luxury Hair Care Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/luxury-hair-care-products-global-market-report

Retail And Wholesale Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/retail-and-wholesale-global-market-report

Personal Care Ingredients Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/personal-care-ingredients-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the ankylosing spondylitis market right now?

Over the past few years, the market size for ankylosing spondylitis has seen robust growth. It is predicted to rise from $5.9 billion in 2024 to $6.36 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. Several factors have spurred growth in the historical period, including the discovery of HLA-B27, the development of biologic treatments, advancements in pain management strategies, increased patient advocacy and awareness, the use of NSAIDS, and disease-modifying drugs.

How fast Is the ankylosing spondylitis market expected to grow, and what’s its future value?

In the coming years, the market size of ankylosing spondylitis is predicted to experience significant growth, anticipated to reach $8.71 billion by 2029 with a compound annual growth rate (CAGR) of 8.2%. This growth during the predicted timeframe can be credited to factors like the approach of personalized medicine, the evolution of novel biologics, early involvement and screenings, management of lifestyle and diet, as well as telemedicine and remote patient monitoring. The future market trends are expected to focus on the availability of biosimilars, targeted therapies for pain management, importance of patient-reported outcomes (pros), community-oriented support programs, and exploring regenerative medicine.

Get your ankylosing spondylitis market report here!

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

What are the leading drivers of growth in the ankylosing spondylitis market?

The rise in the elderly population is predicted to fuel the expansion of the ankylosing spondylitis market in future. The term “geriatric population” denotes an upsurge in the count of senior citizens driven by alterations in a population’s age composition. This demographic transition has escalated the quantity and percentage of individuals over 60 years old. Medications and treatments for ankylosing spondylitis assist in enhancing mobility and controlling pain among seniors afflicted with the condition. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a division of the UN Secretariat located in the US, projected that the worldwide count of those aged 65 and over would more than double, rising from 761 million in 2021 to 1.6 billion by 2050. Consequently, the swelling geriatric population is pushing the ankylosing spondylitis market’s growth.

What are the key segments defining the ankylosing spondylitis market?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Who are the key players steering the development of the ankylosing spondylitis market?

Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

What emerging trends are influencing the growth of the ankylosing spondylitis market?

The focus on the development of new therapeutic options is becoming a prevalent trend in the ankylosing spondylitis market. Ankylosing spondylitis enterprises are introducing innovative therapeutic options to maintain their market dominance. A prime example took place in April 2022 when US biopharmaceutical firm AbbVie Inc. received U.S. Food and Drug Administration (FDA) approval for RINVOQ, a medication designed for the treatment of adults suffering from active ankylosing spondylitis (AS). This opens up a new oral treatment pathway for patients who haven’t had success with TNF blockers, demonstrated by substantial improvements in disease symptoms like back pain and physical functioning. The swift effectiveness and safety profile exhibited in clinical trials position it as an important step forward in managing this chronic inflammatory disease, broadening the range of therapeutic options accessible to patients.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11962

Which regions are most influential in expanding the ankylosing spondylitis market?

North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Luxury Hair Care Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/luxury-hair-care-products-global-market-report

Retail And Wholesale Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/retail-and-wholesale-global-market-report

Personal Care Ingredients Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/personal-care-ingredients-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: